Castrate resistant prostate cancer (CRPC) develops after the use of androgen deprivation therapy has failed to control prostate cancer growth and symptoms. It is an advanced stage of prostate cancer that does not respond to medical or surgical treatments that lower testosterone. The available drugs for castrate resistant prostate cancer include chemotherapy, immunotherapy and hormonal therapy. Chemotherapeutic agents used in management of castrate resistant prostate cancer include docetaxel, cabazitaxel and others. Immunotherapies available for treatment include sipuleucel-T and second generation immunotherapy agents like pembrolizumab are under clinical trials. Hormonal therapies include abiraterone acetate and enzalutamide. Xtandi and Zytiga are the oral hormonal therapies approved for treatment of metastatic castrate resistant prostate cancer.
The global Castrate Resistant Prostate Cancer Market is estimated to be valued at US$ 12.82 Mn in 2024 and is expected to exhibit a CAGR of 6.6% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Increasing use of targeted therapy: As mentioned in the heading, the use of targeted therapy for castrate resistant prostate cancer has increased over the past few years. Targeted therapies like Sipuleucel-T, Abiraterone acetate and Enzalutamide have proven efficacy and better safety profile compared to chemotherapy. This has driven their adoption in management of castrate resistant prostate cancer globally.
Emergence of novel therapies: Several pharmaceutical companies are conducting clinical trials to develop novel therapies for castrate resistant prostate cancer. Some promising drug candidates in clinical trials include ODM-201, Darolutamide, Apalutamide, Relugolix and others. Potential approval of these therapies is expected to further boost the market growth during the forecast period.
The global Castrate Resistant Prostate Cancer market is dominated by the chemotherapy segment which has a market share of around 40%. Chemotherapy drugs are an important treatment option for patients suffering from advanced prostate cancer which has spread to other parts of the body. Drugs like docetaxel, mitoxantrone are commonly used as chemotherapy to slow down the growth and spread of castrate resistant prostate cancer cells. The immunotherapy segment is expected to witness the fastest growth during the forecast period. Immuno-oncology drugs which boost the body’s natural defences to fight cancer cells are gaining popularity. Drugs like sipuleucel-T are effective immunotherapy options for castrate resistant prostate cancer.
Political: Healthcare reforms in various countries are focusing on better access to cancer treatments. Governments provide funding for cancer drug research and development.
Economic: Rising healthcare expenditures due to increasing castrate resistant prostate cancer burden is pushing up the overall market value. Growing demand for advanced targeted therapies is driving investments by pharmaceutical companies.
Social: Higher awareness about prostate cancer diagnosis and treatment options is encouraging patients to seek timely intervention. Non-profit organizations support research on novel drugs.
Technological: Adoption of combination therapies using immunotherapies along with chemotherapy is an emerging trend. Biomarker development aids tailoring of therapies based on individual patient profiles.
Global Castrate Resistant Prostate Cancer Market Size is estimated to be valued at US$ 12.82 billion in 2024 and is expected to exhibit a CAGR of 6.6% over the forecast period 2024-2031.
North America currently dominates the market and is expected to maintain its leading position during the forecast period. Increasing adoption of innovative drugs and availability of advanced healthcare facilities are major factors contributing to the large market share of North America.
Key players operating in the Castrate Resistant Prostate Cancer market are Bucher Vaslin, Pera Pellenc, Scharfenberger, Zambelli Enotech, ENOTOOLS, Criveller Group, Della Toffola, Gruppo Bertolaso, Fabbri, Mori Luigi & C.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it